永昕生物醫藥股份有限公司
永昕生物醫藥股份有限公司（Mycenax Biotech Inc.）在台灣提供生物藥開發與生產服務。服務包含程式開發、細胞株建置、製程開發技術平台、藥物特性分析、檢測方法建立及符合 PIC/S GMP 規範之藥物生產。提供質體 DNA、抗體藥物複合體（ADC）及外泌體等產品。公司成立於 2001 年，總部位於台灣竹北。
該股 RSI(6) 為 25.2，處於偏低區間，短線賣壓漸緩。股價跌破5日、20日、60日、120日均線。短中期均線呈空頭排列，趨勢偏空。KD 指標偏低（K=18.5），有反彈空間；MACD 柱狀體為負值，空方動能持續。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 09-24 | -33 | 0 | 0 | -33 |
| 09-23 | -1 | 0 | 0 | -1 |
| 09-22 | +33 | 0 | 0 | +33 |
| 09-21 | +9 | 0 | 0 | +9 |
| 09-18 | +55 | 0 | 0 | +55 |
| 09-17 | -5 | 0 | +2 | -5 |
| 09-16 | -46 | 0 | 0 | -46 |
| 09-15 | -53 | 0 | 0 | -53 |
| 09-14 | +6 | 0 | +2 | +7 |
| 09-11 | -90 | 0 | 0 | -91 |
| 09-10 | -50 | 0 | +4 | -49 |
| 09-09 | +15 | 0 | 0 | +15 |
| 09-08 | -45 | 0 | 0 | -45 |
| 09-07 | -56 | 0 | 0 | -56 |
| 09-04 | -21 | 0 | 0 | -21 |
| 09-03 | -25 | 0 | 0 | -25 |
| 09-02 | -6 | 0 | 0 | -6 |
| 09-01 | 0 | 0 | 0 | 0 |
| 08-31 | -5 | 0 | 0 | -5 |
| 08-28 | +11 | 0 | +2 | +12 |
| 08-27 | +33 | 0 | 0 | +33 |
| 08-26 | +21 | 0 | 0 | +21 |
| 08-25 | 0 | 0 | 0 | 0 |
| 08-24 | -5 | 0 | 0 | -6 |
| 08-21 | +18 | 0 | 0 | +18 |
| 08-20 | +55 | 0 | 0 | +55 |
| 08-19 | -7 | 0 | +2 | -6 |
| 08-18 | -1 | 0 | 0 | -1 |
| 08-17 | -25 | 0 | +2 | -25 |
| 08-14 | -39 | 0 | 0 | -39 |
| 08-13 | -64 | 0 | 0 | -64 |
| 08-12 | -11 | 0 | +1 | -11 |
| 08-11 | 0 | 0 | 0 | -1 |
| 08-10 | +6 | 0 | +2 | +7 |
| 08-07 | -5 | 0 | 0 | -5 |
| 08-06 | -57 | 0 | 0 | -57 |
| 08-05 | +25 | 0 | 0 | +25 |
| 08-04 | -10 | 0 | 0 | -10 |
| 08-03 | -5 | 0 | 0 | -5 |
| 07-31 | -11 | 0 | 0 | -11 |
| 07-30 | -31 | 0 | 0 | -31 |
| 07-29 | +78 | 0 | 0 | +78 |
| 07-28 | +94 | 0 | 0 | +94 |
| 07-27 | +24 | 0 | 0 | +24 |
| 07-24 | +21 | 0 | 0 | +21 |
| 07-23 | +13 | 0 | 0 | +13 |
| 07-22 | +7 | 0 | 0 | +7 |
| 07-21 | +8 | 0 | 0 | +8 |
| 07-20 | +88 | 0 | +2 | +88 |
| 07-17 | -9 | 0 | +2 | -9 |
| 07-16 | -45 | 0 | 0 | -47 |
| 07-15 | +11 | 0 | +1 | +11 |
| 07-14 | +55 | 0 | 0 | +55 |
| 07-13 | +19 | 0 | +4 | +20 |
| 07-09 | +15 | 0 | 0 | +14 |
| 07-08 | -47 | 0 | 0 | -47 |
| 07-07 | +35 | 0 | +2 | +36 |
| 07-06 | -62 | 0 | +2 | -63 |
| 07-03 | +62 | 0 | 0 | +62 |
| 07-02 | +4 | 0 | 0 | +4 |
| 07-01 | -22 | 0 | 0 | -22 |
| 06-30 | -41 | 0 | 0 | -41 |
| 06-29 | +35 | 0 | +9 | +36 |
| 06-26 | -51 | 0 | 0 | -51 |
| 06-25 | -98 | 0 | 0 | -98 |
| 06-24 | +82 | 0 | +2 | +82 |
| 06-23 | +52 | 0 | 0 | +52 |
| 06-22 | -63 | 0 | +8 | -62 |
| 06-18 | -8 | 0 | 0 | -9 |
| 06-17 | +49 | 0 | 0 | +49 |
| 06-16 | +110 | 0 | +2 | +110 |
| 06-15 | -81 | 0 | +4 | -81 |
| 06-12 | +35 | 0 | +2 | +36 |
| 06-11 | -152 | 0 | +4 | -153 |
| 06-10 | -297 | 0 | +10 | -297 |
| 06-09 | -8 | 0 | 0 | -8 |
| 06-08 | -23 | 0 | 0 | -23 |
| 06-05 | -35 | 0 | 0 | -35 |
| 06-04 | -24 | 0 | 0 | -24 |
| 06-03 | +121 | 0 | +2 | +121 |
| 06-02 | +97 | 0 | 0 | +97 |
| 06-01 | +102 | 0 | +2 | +102 |
| 05-29 | +115 | 0 | +2 | +117 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 1.07 億 | +12.9% | +301.0% |
| 2026/03 | 9456 萬 | +67.1% | +78.6% |
| 2026/02 | 5659 萬 | +23.9% | +140.4% |
| 2026/01 | 4566 萬 | -64.1% | +0.9% |
| 2025/12 | 1.27 億 | +45.0% | +156.4% |
| 2025/11 | 8779 萬 | +26.3% | -19.5% |
| 2025/10 | 6950 萬 | +194.6% | +97.0% |
| 2025/09 | 2359 萬 | -48.4% | -60.6% |
| 2025/08 | 4574 萬 | -26.3% | -33.8% |
| 2025/07 | 6204 萬 | -41.1% | -22.5% |
| 2025/06 | 1.05 億 | +49.4% | +20.3% |
| 2025/05 | 7054 萬 | - | +18.4% |